Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer

Conclusion: STK11/LKB1 expression, as measured by immunohistochemistry, could be a useful biomarker associated with the efficacy of pembrolizumab monotherapy for patients with NSCLC and a TPS ≥50%.

Source: In Vivo - August 30, 2020 Category: Research Authors: HASEGAWA, T., YANAGITANI, N., NINOMIYA, H., SAKAMOTO, H., TOZUKA, T., YOSHIDA, H., AMINO, Y., UEMATSU, S., YOSHIZAWA, T., ARIYASU, R., UCHIBORI, K., KITAZONO, S., HORIIKE, A., NISHIO, M. Tags: Clinical Studies Source Type: research